Novel Compounds for the Prevention and Treatment of Clostridium difficile Infections

Description:

 Novel Compounds for the Prevention and Treatment of Clostridium difficile Infections

Dr. Charles Darkoh has identified and developed novel compounds that may reduce or inhibit toxin production and toxin activity, which directly and selectively targets the cause of C. difficile-associated illness. Dr. Darkoh has further developed potential combination cocktails of these novel compounds which may be used as comprehensive and effective therapeutics for the treatment of both initial and recurrent C. difficile infections. This method of treatment does not affect cell growth and as a result, drug resistance may be greatly reduced due to lack of selective pressure. Furthermore, this approach may promote intestinal homeostasis, which decreases the recovery time and reduce the relapse rates. This novel non-antibiotic treatment option directly targets the cause of the disease and is a promising approach to prevent and treat C. difficile infections.

 

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
Category(s):
Diagnostics
Therapeutics
For Information, Contact:
Hannah Nelson
Senior Technology License Associate
University of Texas Health Science Center At Houston
hannah.m.nelson@uth.tmc.edu
Inventors:
Charles Darkoh
Keywords:
© 2020. All Rights Reserved. Powered by Inteum